Extension of Intravenous Tubing and Pumps Outside Rooms for Safety and Efficiency

Ellen Le; Ruben Lopez; Cayla Moreau; Sharon Foster; Evangeline Galera; Charity Shelton; Anita Catlin

doi:10.4037/ccn2021107

Changing Intravenous Tubing Containing Burettes

JAMA ◽

10.1001/jama.1985.03350250050016 ◽

1985 ◽

Vol 253 (1) ◽

pp. 42 ◽

Cited By ~ 1

Author(s):

Adele Josephson

Keyword(s):

Intravenous Tubing

Download Full-text

SAFETY APPARATUS FOR INTRAVENOUS THERAPY

PEDIATRICS ◽

10.1542/peds.7.4.563 ◽

1951 ◽

Vol 7 (4) ◽

pp. 563-564

Author(s):

JOHN P. FLETCHER

Keyword(s):

Blood Level ◽

Calcium Gluconate ◽

Intravenous Therapy ◽

Intravenous Tubing ◽

Intravenous Medication

THE administration of potent drugs and fluids intravenously often requires much more accurate control than is possible with the usual drip method. This is particularly applicable in the case of small infants for the following reasons: 1. Due to change in position of the infant or relaxation of spasm in the vein receiving the fluid, there may be large variations in the rate of flow, resulting in under-or over-hydration. In the latter case, excessive administration of water or specific electrolytes may cause death in an acutely ill patient. 2. Rates of flow of 10 to 15 cc. per hour are often desirable. It has been found to be impractical to measure a 15 cc. per hour outflow from a 500 cc. flask. Consequently, the nurses must frequently slow down the rate of flow so that stoppages often occur. 3. Certain intravenous medication—notably sodium sulphadiazine, penicillin and calcium gluconate—when injected into standard intravenous tubing, results in massive intermittent dosage. It is more desirable to give continuous intravenous therapy, maintaining the blood level at a uniform concentration. Crystallization of sodium sulphadiazine in the intravenous tubing has been observed when the drug is injected intermittently. This results in a stoppage of the intravenous and irritation of the vein. A simple graduated safety cylinder (chart 1) has been designed to overcome these difficulties.

Download Full-text

Pseudomonas

Revision Notes for MCEM Part A ◽

10.1093/med/9780199583836.003.0021 ◽

2011 ◽

pp. 188-189

Author(s):

Dr Mark Harrison

Keyword(s):

Pseudomonas Aeruginosa ◽

Soil Water ◽

Clinical Features ◽

Hospital Setting ◽

Principles Of Treatment ◽

Intravenous Tubing ◽

Water Plants ◽

Hot Tubs

9.1 Basis of infection, 189 9.2 Clinical features of infection, 189 9.3 Basis of diagnosis, 189 9.4 Principles of treatment, 190 9.5 Implications within hospital setting, 190 • Pseudomonas aeruginosa is the primary pathogen. • Found in soil, water, plants, and animals. • Grows in moist environments including hot tubs, wet intravenous tubing, and other water-containing vessels....

Download Full-text

Effect of Intravenous Tubing Lumen Diameter on Drug Delivery

Developmental Pharmacology and Therapeutics ◽

10.1159/000457172 ◽

1984 ◽

Vol 7 (4) ◽

pp. 259-262 ◽

Cited By ~ 5

Author(s):

Lawrence L. Arwood ◽

Leandro Cordero, Jr. ◽

James A. Visconti

Keyword(s):

Drug Delivery ◽

Lumen Diameter ◽

Intravenous Tubing

Download Full-text

Insulin Adsorption by Glass Infusion Bottles, Polyvinylchloride Infusion Containers, and Intravenous Tubing

Anesthesiology ◽

10.1097/00000542-197404000-00018 ◽

1974 ◽

Vol 40 (4) ◽

pp. 400-404 ◽

Cited By ~ 68

Author(s):

CLAYTON PETTY ◽

NELSON L. CUNNINGHAM ◽

MAJOR

Keyword(s):

Intravenous Tubing

Download Full-text

Y-site Incompatibility between Premix Concentrations of Vancomycin and Piperacillin-Tazobactam: Do Current Compatibility Testing Methodologies Tell the Whole Story?

Hospital Pharmacy ◽

10.1310/hpj5202-132 ◽

2017 ◽

Vol 52 (2) ◽

pp. 132-137 ◽

Cited By ~ 5

Author(s):

Wesley D. Kufel ◽

Christopher D. Miller ◽

Paul R. Johnson ◽

Kaleigh Reid ◽

James J. Zahra ◽

...

Keyword(s):

Clinical Setting ◽

Visual Inspection ◽

Compatibility Studies ◽

Site Testing ◽

Visual Evidence ◽

Site Evaluation ◽

Smart Pumps ◽

Intravenous Tubing ◽

And Control ◽

Antibiotic Infusion

Background Published literature has demonstrated commercially available premix vancomycin (5 mg/mL) and piperacillin-tazobactam (67.5 mg/mL) as physically compatible via simulated Y-site methodology. Compatibility via actual Y-site infusion has yet to be established. Objective To assess and compare the compatibility of commercially available premix concentrations of vancomycin and piperacillin-tazobactam via simulated and actual Y-site evaluation. Methods Vancomycin and piperacillin-tazobactam were tested using simulated and actual Y-site infusion methodologies. Simulated Y-site compatibility was performed using previously published methods via visual inspection, turbidity evaluation, and pH evaluation. Evaluation occurred immediately, 60 minutes, 120 minutes, and 240 minutes following mixing for each mixture and control. Mixtures were considered physically incompatible if there was visual evidence of precipitation or haze, an absorbance value was greater than 0.01 A, or an absolute change of 1.0 pH unit occurred. Actual Y-site infusion was simulated to mirror antibiotic infusion in the clinical setting by nursing personnel using smart pumps and intravenous tubing. Results No evidence of physical incompatibility was observed during simulated Y-site testing via visual inspection, turbidity assessment, and pH evaluation. Conversely, physical incompatibility was observed to the unaided eye within 2 minutes during actual Y-site infusion. Conclusions Despite observed compatibility between vancomycin and piperacillin-tazobactam via simulated Y-site testing, visual evidence of physical incompatibility was observed during actual Y-site infusion. This poses a potential compromise to patient safety if these antibiotics are administered simultaneously in the clinical setting. Actual Y-site testing should be performed prior to clinical adoption of compatibility studies that are based solely on simulated methodologies.

Download Full-text